Skip to main content

Table 3 Overall changes from baseline in glucose metabolism parameters and serum lipids and apolipoproteins

From: Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study

Parameter

Adjusted overall change (95% CI)*

P†

Ipragliflozin

Sitagliptin

Difference

Interaction

Glucose metabolism

    

 FPG (mmol/L)

−1.28 (− 1.56; −1.00)

−1.24 (− 1.51; −0.96)

0.83

0.04

 Insulin (pmol/L)

−8.51 (− 14.7; −2.34)

−3.83 (− 9.39; 1.74)

0.27

0.75

 HbA1c (%)

−0.33 (− 0.45; −0.22)

−0.44 (− 0.55; −0.33)

0.19

0.14

 GA (%)

−1.97 (− 2.35; −1.58)

−2.07 (− 2.44; −1.69)

0.72

0.29

Lipids

    

 TC (mg/dL)

1.7 (− 3.6; 6.9)

−1.8 (− 6.8; 3.3)

0.36

0.84

 LDL-C (mg/dL)

1.2 (− 3.1; 5.6)

6.6 (1.6; 11.6)

0.12

0.40

 HDL-C (mg/dL)

2.3 (0.9; 3.6)

0.0 (− 1.2; 1.3)

0.02

0.59

 TG (mg/dL)

−12.7 (− 30.3; 4.9)

−23.1 (− 40.7; −5.4)

0.42

0.92

Apolipoproteins

    

 AI (mg/dL)

2.26 (− 0.89; 5.40)

−1.68 (− 4.23; 0.87)

0.06

0.86

 AII (mg/dL)

−0.51 (− 1.17; 0.16)

−0.18 (− 0.74; 0.39)

0.46

0.26

 B (mg/dL)

−0.69 (− 3.90; 2.52)

−1.96 (− 4.74; 0.81)

0.55

0.59

 B48 (µg/dL)

0.45 (− 0.60; 1.49)

−1.39 (− 2.16; −0.61)

0.006

0.11

 CII (mg/dL)

−0.21 (− 0.51; 0.09)

−0.40 (− 0.64; −0.17)

0.31

0.71

 CIII (mg/dL)

−0.07 (− 0.85; 0.72)

−0.86 (− 1.38; −0.34)

0.10

0.51

 E (mg/dL)

−0.30 (− 0.56; −0.05)

−0.09 (− 0.30; 0.11)

0.21

0.91

  1. Follow-up measurements were done at 1, 3, and 6 months
  2. *, Based on a mixed-model repeated-measures analysis adjusting for sex, age, and baseline value of a parameter of interest
  3. †, P < 0.05 indicates the statistical significance for the between-treatment difference and treatment-month interaction
  4. CI, confidence interval; FPG, fasting plasma glucose; GA, glycoalbumin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides